News | PET Imaging | July 16, 2020

Novel imaging agent provides foundation to inform treatment strategies

Novel imaging agent provides foundation to inform treatment strategies

Getty Images


July 16, 2020 — Whole body positron emission tomography (PET) has, for the first time, illustrated the existence of inter-organ communication between the heart and kidneys via the immune system following acute myocardial infarction, or heart attack. According to research presented at the Society of Nuclear Medicine and Molecular Imaging's 2020 Annual Meeting, the identification of a systemic inflammatory response to myocardial infarction has the potential to assist physicians in identifying patients most at risk of disease progression and most likely to respond to therapy.

Patients with acute myocardial infarction often develop impaired kidney function, thought to be mediated by the activation and mobilization of immune cells, or inflammation. While inflammation is necessary for effective healing, uncontrolled inflammatory cell activity can be detrimental for both the heart and the kidneys. To further understand the mechanics of this bidirectional interaction, researchers conducted a preclinical analysis of a novel imaging agent that targets inflammatory cells after myocardial infarction.

Using serial whole-body CXCR4-targeted 68Ga-pentixafor PET, researchers imaged 65 mice after surgically-induced myocardial infarction or sham surgery at one day, three days, seven days and six weeks. Tracer retention was determined in the kidneys and compared to infarct signal and cardiac function, as measured independently by magnetic resonance.

Cardiac CXCR4 signal was significantly elevated on the first day of imaging and returned to sham level after seven days. Renal CXCR4 signal was unchanged on the first day of imaging, but was reduced after seven days as compared to sham levels. Cardiac and renal signal were directly correlated, suggesting an inflammatory link between the heart and the kidneys. Ex-vivo autoradiography confirmed a significant correlation between tracer retention in the myocardial infarction region and the kidneys.

"This study provides a foundation for simultaneous examination of heart and kidneys after myocardial infarction by using molecular imaging," noted Rudolf Werner, M.D., Ph.D., resident in the department of nuclear medicine at Hannover Medical School in Hannover, Germany. "It provides an impetus for the pursuit of systems-based multi-organ imaging to investigate systemic response to focal injury."

He continued, "Assessment of inflammation after myocardial infarction is beginning to be evaluated in clinical populations. With the growth of long-bore cameras with larger fields of view, the concept of multi-organ imaging will expand substantially in the next years.

In the future, nuclear medicine techniques may identify the optimal patient and time point for anti-inflammatory therapy, and identify the added risk to off-target organs after primary injury."

For more information: www.snmmi.org

 

Related SNMMI20 Content:

SNMMI Channel

PSMA PET/CT Can Change Management in Recurrent Prostate Cancer

Total-body Dynamic PET Successfully Detects Metastatic Cancer

New PET Radiotracer Proven Safe in Imaging Malignant Brain Tumors

Targeted Radionuclide Therapy Enhances Prostate Cancer Response to Immunotherapies

New PET/MRI Approach Pinpoints Chronic Pain Location, Alters Management

 

Related Content

News | Prostate Cancer

July 30, 2024 — Blue Earth Diagnostics, a Bracco company and recognized leader in the development and commercialization ...

Time July 30, 2024
arrow
News | Radiopharmaceuticals and Tracers

July 25, 2024 — NorthStar Medical Radioisotopes, LLC and BWXT Medical Ltd., a subsidiary of BWX Technologies, Inc ...

Time July 25, 2024
arrow
News | PET-CT

July 25, 2024 — Positron Corporation, a leading molecular imaging medical device company offering PET & PET-CT imaging ...

Time July 25, 2024
arrow
News | Radiology Imaging

July 23, 2024 — EMVision, an Australian medical device company focused on the development and commercialization of ...

Time July 23, 2024
arrow
News | PET-CT

July 16, 2024 — A new research paper was published in Oncotarget's Volume 15 on June 20, 2024, titled, “Comparison of ...

Time July 16, 2024
arrow
News | Computed Tomography (CT)

July 15, 2024 — NeuroLogica Corp, a subsidiary of Samsung Electronics Co. Ltd., announced its latest configuration of ...

Time July 15, 2024
arrow
News | Prostate Cancer

July 5, 2024 — Lantheus Holdings, Inc., a leading radiopharmaceutical-focused company committed to enabling clinicians ...

Time July 05, 2024
arrow
News | Prostate Cancer

July 2, 2024 — A new editorial paper was published in Oncoscience (Volume 11) on May 20, 2024, entitled, “Deep learning ...

Time July 02, 2024
arrow
Feature | SCCT | by Christine Book

June 27, 2024 — The countdown has begun for the Society of Cardiovascular Computed Tomography (SCCT) 19th Annual ...

Time June 27, 2024
arrow
News | ASTRO

June 21, 2024 — The American Society for Radiation Oncology (ASTRO) announced today that following a nationwide search ...

Time June 21, 2024
arrow
Subscribe Now